The effectiveness of famotidine for improving the outcomes of hospitalized COVID-19 Patients.

Key Messages

These are the results of the first randomized controlled clinical trial to test the drug famotidine for treating COVID-19 patients.

This study included 20 hospitalized patients with COVID-19 (mean age of 46 +/- 13 years). Ten patients were given a high dose of oral famotidine (160 mg) four times a day for a maximum of 14 days or until they were discharged and 10 patients were given a placebo. Both groups of patients otherwise received standard treatment for COVID-19.

Among the patients who took famotidine, the length of hospitalization was reduced by an average of 3 days, blood oxygen levels were improved, and they showed a significant reduction in coughing.

Famotidine-treated patients also had decreased levels of lactate dehydrogenase (LDH) levels, an indicator of tissue damage, and lower white blood cell (WBC) counts compared to patients receiving the placebo.

Research Square

Publication Date: April 27, 2021
Peer Reviewed: No
Publication Type: Original | Clinical Prospective

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial

Hamid Reza Samimagham, Mehdi Hassani Azad, Maryam Haddad, Mohsen Arabi, Dariush Hooshyar, Mitra KazemiJahromi


As the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.

This phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation, and recruited 20 patients. Oral Famotidine 160 mg four times a day was given to patients until the discharge day or for a maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.

The results showed a significant decrease in LDH (P = 0.01), mean WBC (P = 0.04) and length of stay (P = 0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P = 0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P = 0.02).

This was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.